<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036981</url>
  </required_header>
  <id_info>
    <org_study_id>2018-KAE-0230</org_study_id>
    <nct_id>NCT04036981</nct_id>
  </id_info>
  <brief_title>Muscle Selection for Botulinum Toxin A Injection in Poststroke Elbow Flexor Spasticity</brief_title>
  <official_title>The Effect of Muscle Selection for Botulinum Toxin A Injection on the Treatment Outcome in Poststroke Elbow Flexor Spasticity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Izmir Katip Celebi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Izmir Katip Celebi University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum toxin A (BoNT A) has been reported to be effective in the treatment of elbow flexor
      spasticity. Although BoNT A is an efficacious treatment option, there is a debate in the
      selection of target muscle(s) for BoNT injection in the treatment of poststroke elbow flexor
      spasticity. The decision of muscle selection for BoNT A injection is mostly made according to
      the physical examination findings in real life practice.One of the guiding findings in this
      decision is the position of the spastic arm.

      In this study, hypothesis is that the change in severity of spasticity with BoNT A injection
      differs depending on the muscle selection in chronic stroke patients with elbow flexor and
      forearm pronator spasticity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Botulinum neurotoxin A (BoNT A) has been reported to be effective in the treatment of elbow
      flexor spasticity. In the treatment of poststroke elbow flexor spasticity with BoNT A, three
      main muscles injected individually or in combination are musculus biceps brachii, musculus
      brachialis and musculus brachioradialis. Although BoNT is an efficacious treatment option,
      there is a debate in the selection of target muscle(s) for BoNT A injection in the treatment
      of poststroke elbow flexor spasticity. Superficiality of the biceps brachii muscle makes it
      an easy target for botulinum toxin injection. In dynamic electromyography studies, it has
      been reported that brachioradialis muscle is the most common contributor one to elbow flexion
      spasticity, followed by biceps brachii muscle. In the diagnostic selective nerve blocks, the
      brachialis muscle has been reported to be foreground. In a recent study using the modified
      Delphi Method Design, the expert committee was only fully agree on the application of BoNT A
      into the brachioradialis muscle.

      The decision of muscle selection for BoNT A injection is mostly made according to the
      physical examination findings in real life practice. One of the guiding findings in this
      decision is the position of the spastic arm. The typical pattern of spastic elbow and forearm
      in patients with stroke is characterized by flexion at the elbow, and pronation in the
      forearm. As far as the investigators know, there has not been carried out any study
      investigating the effect of muscle selection for BoNT application on the treatment outcome
      (severity of spasticity) in chronic stroke patients with elbow flexor and forearm pronator
      spasticity.

      The aim of this study is to investigate whether treatment response (change in severity of
      spasticity) differs according to BoNT A injected muscle in chronic stroke patients with elbow
      flexor and forearm pronator spasticity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic Component of Spasticity (Spasticity Angle)</measure>
    <time_frame>up to 4 week</time_frame>
    <description>According to the Modified Tardieu Scale, the difference between the angle of slow passive motion and the angle of muscle reaction represents the dynamic component of spasticity (spasticity angle) in degree. A big difference suggests spasticity while the low difference suggests muscular contracture. In this study, dynamic component of spasticity (spasticity angle) of elbow joint at forearm pronation position will be evaluated.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Muscle Spasticity</condition>
  <arm_group>
    <arm_group_label>Brachialis</arm_group_label>
    <description>Targeted muscle for BoNT A injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biceps</arm_group_label>
    <description>Targeted muscle for BoNT A injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brachioradialis</arm_group_label>
    <description>Targeted muscle for BoNT A injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combinations</arm_group_label>
    <description>Targeted muscles for BoNT A injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles</description>
    <arm_group_label>Biceps</arm_group_label>
    <arm_group_label>Brachialis</arm_group_label>
    <arm_group_label>Brachioradialis</arm_group_label>
    <arm_group_label>Combinations</arm_group_label>
    <other_name>Botox</other_name>
    <other_name>Dysport</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Stroke patients with elbow flexor and forearm pronator spasticity
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic (equal to or upper than 1 year) stroke patients with position of elbow flexion
             and forearm pronation while standing or sitting

          -  Grade 2 or 3 elbow flexor spasticity and grade 1 to 3 forearm pronator spasticity
             according to Modified Ashworth Scale

          -  Stage 2 or 3 Brunnstrom's motor recovery stage of upper extremity

          -  To agree to participate in the study

        Exclusion Criteria:

          -  &lt;18 years old

          -  Pregnancy

          -  Botulinum toxin injection within the last three months

          -  Presence of elbow contracture

          -  History of operation to spastic upper extremity

          -  Spasticity due to other causes other than stroke

          -  Do not agree to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>İlker Şengül, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Izmir Katip Celebi University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>İlker Şengül, M.D.</last_name>
    <phone>+905337333698</phone>
    <email>ilkrsngl@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayhan Aşkın, M.D.</last_name>
    <phone>+905327621932</phone>
    <email>ayhanaskın@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>İlker Şengül</name>
      <address>
        <city>İzmir</city>
        <state>In The USA Or Canada, Please Select...</state>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İlker Şengül, M.D.</last_name>
      <phone>05337333698</phone>
      <email>ilkrsngl@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ayhan Aşkın, M.D.</last_name>
      <phone>05327621932</phone>
      <email>ayhanaskin@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>İlker Şengül, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayhan Aşkın, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aliye Tosun, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Keenan MA. Management of the spastic upper extremity in the neurologically impaired adult. Clin Orthop Relat Res. 1988 Aug;(233):116-25. Review.</citation>
    <PMID>3042230</PMID>
  </reference>
  <reference>
    <citation>Genet F, Schnitzler A, Droz-Bartholet F, Salga M, Tatu L, Debaud C, Denormandie P, Parratte B. Successive motor nerve blocks to identify the muscles causing a spasticity pattern: example of the arm flexion pattern. J Anat. 2017 Jan;230(1):106-116. doi: 10.1111/joa.12538. Epub 2016 Sep 6.</citation>
    <PMID>27595994</PMID>
  </reference>
  <reference>
    <citation>Keenan MA, Haider TT, Stone LR. Dynamic electromyography to assess elbow spasticity. J Hand Surg Am. 1990 Jul;15(4):607-14.</citation>
    <PMID>2380525</PMID>
  </reference>
  <reference>
    <citation>BASMAJIAN JV, LATIF A. Integrated actions and functions of the chief flexors of the elbow: a detailed electromyographic analysis. J Bone Joint Surg Am. 1957 Oct;39-A(5):1106-18.</citation>
    <PMID>13475410</PMID>
  </reference>
  <reference>
    <citation>Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206-7.</citation>
    <PMID>3809245</PMID>
  </reference>
  <reference>
    <citation>Gracies JM, Bayle N, Vinti M, Alkandari S, Vu P, Loche CM, Colas C. Five-step clinical assessment in spastic paresis. Eur J Phys Rehabil Med. 2010 Sep;46(3):411-21.</citation>
    <PMID>20927007</PMID>
  </reference>
  <reference>
    <citation>Hefter H, Jost WH, Reissig A, Zakine B, Bakheit AM, Wissel J. Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment? Int J Rehabil Res. 2012 Sep;35(3):227-33. doi: 10.1097/MRR.0b013e328353e3d4.</citation>
    <PMID>22555318</PMID>
  </reference>
  <reference>
    <citation>Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Esquenazi A, Graham GD, McGuire JR, Odderson I. OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process. PM R. 2017 Feb;9(2):136-148. doi: 10.1016/j.pmrj.2016.06.016. Epub 2016 Jun 23.</citation>
    <PMID>27346090</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Izmir Katip Celebi University</investigator_affiliation>
    <investigator_full_name>ilker şengül</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Muscle spasticity</keyword>
  <keyword>Botulinum toxin A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

